RecruitingNot ApplicableNCT07107165

Psychosocial and Behavioral Intervention for Stem Cell Transplant Patients and Their Family Caregivers

Adapting After Discharge From Allogeneic SCT: Partnering Together; Dyadic Intervention to Improve Patient-Family Caregiver Team-Based Management of the Medical Regimen After Allogeneic Hematopoietic Cell Transplantation

Sponsor

University of Pittsburgh

Enrollment

208 participants

Start Date

Jul 1, 2025

Study Type

INTERVENTIONAL

Conditions

Stem Cell Transplant Hematopoetic Stem Cell Transplantation Hematopoetic Stem Cell Transplant

Summary

Adherence to the medical regimen after stem cell transplant is challenging for both patients and their family caregivers. The investigators propose a randomized clinical trial testing two brief psychosocial interventions to determine if either improves patient and family caregiver psychosocial and health-related outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Dyadic Problem Solving Training and a behavioral approach called Supportive Care for people with hematopoetic stem cell transplant, hematopoetic stem cell transplantation, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALDyadic Problem Solving Training

DPST consists of teaching the patient and family caregiver problem-solving skills that they can apply to help them manage the medical regimen after stem cell transplant.

BEHAVIORALSupportive Care

Supportive Care consists of providing support to the patient and family caregiver as they manage the medical regimen after stem cell transplant

Locations(1)

University of Pittsburgh Medical Center Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07107165

Related Trials

Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease

NCT072520504 locations

Shingrix In Recipients of Allogeneic Transplants

NCT057757181 location